Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/Ipr mice via both complement-dependent and -independent mechanisms

American Journal of Pathology

Volumn 170, Issue 4, 2007, Pages 1258-1266

  Miwa, Takashi ^a   Maldonado, Michael A ^a   Zhou, Lin ^a   Yamada, Koei ^a   Gilkeson, Gary S ^b   Eisenberg, Robert A ^a   Song, Wen Chao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY ACCELERATING FACTOR; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERMATITIS; DISEASE SEVERITY; GENE MUTATION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN PROTECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BLOOD; BONE MARROW TRANSPLANTATION; FEMALE; GENETICS; KIDNEY; LYMPH NODE; MALE; METABOLISM; MOUSE MUTANT; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD55; BONE MARROW TRANSPLANTATION; COMPLEMENT C3; DERMATITIS; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPH NODES; MALE; MICE; MICE, INBRED MRL LPR; MICE, KNOCKOUT; ORGAN SIZE; SIGNAL TRANSDUCTION;

EID: 34247842905     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.060601     Document Type: Article

References (44)

1. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V: Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987, 165:848-864
2. Miwa T, Sun X, Ohta R, Okada N, Harris CL, Morgan BP, Song WC: Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Immunology 2001, 104:207-214
3. Medof ME, Kinoshita T, Silber R, Nussenzweig V: Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci USA 1985, 82:2980-2984
4. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF: Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983, 80:5066-5070
5. Pangburn MK, Schreiber RD, Muller-Eberhard HJ: Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983, 80:5430-5434
6. Rosse WF, Parker CJ: Paroxysmal nocturnal haemoglobinuria. Clin Haematol 1985, 14:105-125
7. Telen MJ, Hall SE, Green AM, Moulds JJ, Rosse WF: Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 1988, 167:1993-1998
8. Lublin DM, Mallinson G, Poole J, Reid ME, Thompson ES, Ferdman BR, Telen MJ, Anstee DJ, Tanner MJ: Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Blood 1994, 84:1276-1282
9. Wang L, Uchikawa M, Tsuneyama H, Tokunaga K, Tadokoro K, Juji T: Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype. Blood 1998, 91:680-684
10. Kim DD, Song WC: Membrane complement regulatory proteins. Clin Immunol 2006, 118:127-136
11. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, Song WC: The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 2005, 201:567-577
12. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof ME: Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005, 201:1523-1530
13. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME: Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002, 110:1269-1274
14. Sogabe H, Nangaku M, Ishibashi Y, Wada T, Fujita T, Sun X, Miwa T, Madaio MP, Song WC: Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 2001, 167:2791-2797
15. Lin F, Emancipator SN, Salant DJ, Medof ME: Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest 2002, 82:563-569
16. Yamada K, Miwa T, Liu J, Nangaku M, Song WC: Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004, 172:3869-3875
17. Lin F, Spencer D, Hatala DA, Levine AD, Medof ME: Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 2004, 172:3836-3841
18. Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, Werth VP, Madaio MP, Eisenberg RA, Song WC: Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 2002, 161:1077-1086
19. Cohen PL, Eisenberg RA: Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991, 9:243-269
20. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317
21. Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosus. Adv Immunol 1985, 37:269-390
22. Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM: Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 1992, 175:121-129
23. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM: Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 1993, 151:4295-4305
24. Holers VM, Kinoshita T, Molina H: The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today 1992, 13:231-236
25. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, Yarme A, Stetler-Stevenson MA, Siebenlist U, Kelly K: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 1996, 157:5438-5447
26. Hamann J, Vogel B, van Schijndel GM, van Lier RA: The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996, 184:1185-1189
27. Tosello AC, Mary F, Amiot M, Bernard A, Mary D: Activation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion. J Inflamm 1998, 48:13-27
28. Stefanová I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 1991, 254:1016-1019
29. Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin DM: Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J Immunol 1992, 149:3535-3541
30. Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove I: Costimulation via CD55 on human CD4+ T cells mediated by CD97. J Immunol 2006, 177:1070-1077
31. Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS: Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001, 166:6444-6451
32. Maldonado MA, Eisenberg RA, Roper E, Cohen PL, Kotzin BL: Greatly reduced lymphoproliferation in lpr mice lacking major histocompatibility complex class I. J Exp Med 1995, 181:641-648
33. Circolo A, Garnier G, Fukuda W, Wang X, Hidvegi T, Szalai AJ, Briles DE, Volanakis JE, Wetsel RA, Colten HR: Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology 1999, 42:135-149
34. Lublin DM, Atkinson JP: Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989, 7:35-58
35. Werth VP, Ivanov IE, Nussenzweig V: Decay-accelerating factor in human skin is associated with elastic fibers. J Invest Dermatol 1988, 91:511-516
36. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC: Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA 1999, 96:628-633
37. Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, Marks PA, Gilkeson GS: Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004, 173:4171-4178
38. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ: Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002, 168:3601-3607
39. Carroll MC: The complement system in regulation of adaptive immunity. Nat Immunol 2004, 5:981-986
40. Walport MJ: Complement. Second of two parts. N Engl J Med 2001, 344:1140-1144
41. Wakui M, Morel L, Butfiloski EJ, Kim C, Sobel ES: Genetic dissection of systemic lupus erythematosus pathogenesis: partial functional complementation between Sle1 and Sle3/5 demonstrates requirement for intracellular coexpression for full phenotypic expression of lupus. J Immunol 2005, 175:1337-1345
42. Chen Y, Perry D, Boackle SA, Sobel ES, Molina H, Croker BP, Morel L: Several genes contribute to the production of autoreactive B and T cells in the murine lupus susceptibility locus Sle1c. J Immunol 2005, 175:1080-1089
43. Xu Z, Duan B, Croker BP, Wakeland EK, Morel L: Genetic dissection of the murine lupus susceptibility locus Sle2: contributions to increased peritoneal B-1a cells and lupus nephritis map to different loci. J Immunol 2005, 175:936-943
44. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC: Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 1995, 92:11490-11494